ABSTRACT
Genistein, an isoflavonoid phytoestrogen, has been known for its potential pharmacological properties especially for neuroprotection and treating diabetes. The present study aims to determine the neuroprotective efficacy of genistein against global cerebral ischemia-reperfusion-induced neuronal injury in streptozotocin-induced diabetic mice and explore the underlying mechanisms. Streptozotocin-induced diabetic mice were subjected to transient cerebral ischemia by occluding both common carotid arteries for 30 min followed by 24 h reperfusion to induce neuronal injury. Effect of genistein (2.5, 5.0, and 10.0 mg/kg, i.p., o.d.) treatment on ischemia-reperfusion-induced neuronal injury in diabetic mice was evaluated in terms of cerebral infarct size, oxidative damage, mitochondrial activity in terms of neuronal apoptosis and cellular viability, dipeptidyl peptidase-4 activity and active glucagon-like peptide-1 concentration, and neurological functions measured as short-term memory and motor performance. Genistein administration following transient cerebral ischemia significantly (p ˂ 0.0001) counteracted cognitive impairment and re-established (p ˂ 0.001) motor performance in diabetic mice. Ischemia-reperfusion increased the infarct size, genistein administration prevented the increase in cerebral infarct size (p ˂ 0.0001) and significantly suppressed (p ˂ 0.001) the increase in cerebral oxidative stress in transient cerebral ischemia-reperfusion subjected diabetic mice. Genistein treatment significantly (p ˂ 0.001) reduced neuronal apoptosis and increased cellular viability (p ˂ 0.0001), almost completely suppressed (p ˂ 0.0001) the circulating dipeptidyl peptidase-4 activity, and enhanced (p ˂ 0.0001) glucagon-like peptide-1 concentration in diabetic mice with cerebral ischemia-reperfusion. This study suggests that genistein has potent neuroprotective activity against global cerebral ischemia-reperfusion-induced neuronal injury and consequent neurological deficits in streptozotocin-induced diabetic mice.
Similar content being viewed by others
REFERENCES
Callaghan, B.C., H.T. Cheng, C.L. Stables, A.L. Smith, and F.L. Feldman. 2012. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurology 11(6): 521–534.
Zhang, Z., J. Yan, and H. Shi. 2013. Hyperglycemia as a risk factor of ischemic stroke. Journal of Drug Metabolism and Toxicology 4(4): 153–165.
Santulli, G. 2013. Epidemiology of cardiovascular disease in 21st century: updated number and updated facts. Journal of Cardiovascular Disease 1(1): 1–2.
Olmez, I., and H. Ozyurt. 2012. Reactive oxygen species and ischemic cerebrovascular disease. Neurochemistry International 60(2): 208–212.
Mohamed, I.N., I. Tauheed, S.C. Fagan, and A.B. El-Remessy. 2015. Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit. Antioxidant and Redox Signaling 22(13): 1188–1206.
Rink, C., Khanna S. Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke. Antioxidant and Redox Signaling 14(10): 1889–1903.
Choi, D.Y., and H. Choi. 2015. Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer’s disease, Parkinson’s disease and ischemic brain stroke: their molecular targets and action mechanisms. Archives of Pharmacal Research 38(2): 139–170.
Rahman, S., R. Islam, A.M. Swaraz, A. Ansari, A.K. Parvez, and D.K. Paul. 2012. An insight on genistein as potential pharmacological and therapeutic agent. Asian Pacific Journal of Tropical Medicine 2(3): 1924–1937.
Behloul, N., and W. Guanzhong. 2013. Genistein: a promising therapeutic agent for obesity and diabetes treatment. European Journal of Pharmacology 698(1–3): 31–38.
Valsecchi, A.E., S. Franchi, A.E. Panerai, A. Rossi, P. Sacerdote, and M. Colleoni. 2011. The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. European Journal of Pharmacology 650(2–3): 694–702.
Rajput, M.S., and P.D. Sarkar. 2016. Neuroprotective potential of genistein in mitochondrial dysfunction mediated apoptosis in diabetic neuronal complications. Journal of Chemical and Pharmaceutical Research 8: 16–24.
Takeda, Y., Y. Fujita, J. Honjo, T. Yanagimachi, H. Sakagami, Y. Takiyama, Y. Makino, A. Abiko, T.J. Kieffer, and M. Haneda. 2012. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55(2): 404–412.
Mohamed, H.E., S.E. El-Swefy, R.A. Hasan, and A.A. Hasan. 2014. Neuroprotective effect of resveratrol in diabetic cerebral ischemic-reperfused rats through regulation of inflammatory and apoptotic events. Diabetology and Metabolic Syndrome 6(1): 88–92.
Zhang, W.N., T. Bast, Y. Yu, and J. Feldon. 2014. Temporary inhibition of dorsal or ventral hippocampus by muscimol: distinct effects on measures of innate anxiety on the elevated plus maze, but similar disruption of contextual fear conditioning. Behavioral Brain Research 262(1): 47–56.
Beckett, T.L., C.M. Studzinski, J.N. Keller, M.M. Paul, and D.M. Niedowicz. 2013. A ketogenic diet improves motor performance but does not affect β-amyloid levels in a mouse model of Alzheimer’s disease. Brain Research 1505(1): 61–67.
Malik, Z.A., M. Singh, and P.L. Sharma. 2011. Neuroprotective effect of Momordica charantia in global cerebral ischemia and reperfusion induced neuronal damage in diabetic mice. Journal of Ethnopharmacology 133(2): 729–734.
Gupta, R., M. Singh, and A. Sharma. 2003. Neuroprotective effect of antioxidants on ischaemia and reperfusion-induced cerebral injury. Pharmacological Research 48(2): 209–215.
Shen, Y.X., K. Xiao, P. Liang, Y.W. Ma, and X. Huang. 2013. Improvement on the modified Lowry method against interference of divalent cations in soluble protein measurement. Applied Microbiology and Biotechnology 97(9): 4167–4178.
Patel, S.S., A. Parashar, and M. Udayabanu. 2015. Urtica dioica leaves modulates muscarinic cholinergic system in the hippocampus of streptozotocin-induced diabetic mice. Metabolic Brain Disease 30(3): 803–811.
Kumar, S.D., M. Vijaya, R.P. Samy, S.T. Dheen, M. Ren, F. Watt, Y.J. Kang, B.H. Bay, and S.S. Tay. 2012. Zinc supplementation prevents cardiomyocyte apoptosis and congenital heart defects in embryos of diabetic mice. Free Radical Biology and Medicine 53(8): 1595–606.
Mishiro, K., T. Imai, S. Sugitani, A. Kitashoji, Y. Suzuki, T. Takagi, H. Chen, Y. Oumi, K. Tsuruma, M. Shimazawa, and H. Hara. 2014. Diabetes mellitus aggravates hemorrhagic transformation after ischemic stroke via mitochondrial defects leading to endothelial apoptosis. PloS One 9(8): e103818.
Singh, A.B., T. Khaliq, J.P. Chaturvedi, T. Narender, and A.K. Srivastava. 2012. Anti-diabetic and anti-oxidative effects of 4-hydroxypipecolic acid in C57BL/KsJ-db/db mice. Human Experimental Toxicology 31(1): 57–65.
Ma, M.J., Y. Hasegawa, N. Koibuchi, K. Toyama, K. Uekawa, T. Nakagawa, B. Lin, and S. Kim-Mitsuyama. 2015. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovascular Diabetology 14(1): 54–58.
Bhathena, S.J., and M.T. Velasquez. 2002. Beneficial role of dietary phytoestrogens in obesity and diabetes. American Journal of Clinical Nutrition 76(6): 1191–1201.
Saczynski, J.S., S. Siggurdsson, P.V. Jonsson, G. Eiriksdottir, E. Olafsdottir, T.B. Harris, M.A. van Buchem, V. Gudnason, and L.J. Launer. 2009. Glycemic status and brain injury in older individuals: the age gene/environment susceptibility-Reykjavik study. Diabetes Care 32(1): 1608–1613.
Prasad, S., R.K. Sajja, P. Naik, and L. Cucullo. 2014. Diabetes mellitus and blood-brain barrier dysfunction: an overview. Journal of Pharmacovigilence 2(2): 125–128.
Cunha, C.D., M. Igoillo-Esteve, E.N. Gurzov, C.M. Germano, N. Naamane, I. Marhfour, et al. 2012. Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress–mitochondrial dialog triggering lipotoxic rodent and human β-cell apoptosis. Diabetes 61(11): 2763–2775.
Cryer, P.E. 2014. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes 63(7): 2188–2195.
Ji, L., X. Zhang, W. Liu, Q. Huang, W. Yang, F. Fu, H. Ma, H. Su, H. Wang, J. Wang, H. Zhang, and F. Gao. 2013. AMPK-regulated and Akt-dependent enhancement of glucose uptake is essential in ischemic preconditioning-alleviated reperfusion injury. PloS One 8(7): e69910.
Soares, E., S. Nunes, F. Reis, and F.C. Pereria. 2012. Diabetic encephalopathy: the role of oxidative stress and inflammation in type 2 diabetes. International Journal of Interferon Cytokine and Mediator Research 4(1): 75–85.
David, R., D.R. McIlwain, T. Berger, and T.W. Mak. 2013. Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology 5(1): a008656.
Luheshi, N.M., K.J. Kovács, G. Lopez-Castejon, D. Brough, and A. Denes. 2011. Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues. Journal of Neuroinflammation 8(1): 186–190.
Ryskjaer, J., C.F. Deacon, R.D. Carr, T. Krarup, S. Madsbad, J. Holst, and T. Vilsboll. 2006. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European Journal of Endocrinology 155(3): 485–493.
Deacon, C.F., and J.J. Holst. 2006. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. International Journal of Biochemical Cell Biology 38(5–6): 831–844.
Cuthbertson, J., S. Patterson, F.P.M. O’Harte, and P.M. Bell. 2009. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes. Diabetic Medicine 26(6): 649–654.
Fan, J., M. Johnson, and E. Gonzalez de Mejia. 2013. Citrus and berry flavonoids inhibit dipeptidyl peptidase-IV enzymatic activity by binding to the catalytic site. The FASEB Journal 27(1): 637–638.
El-Mir, M.Y., D. Detaille, G. R-Villanueva, M. Delgado-Esteban, B. Guigas, S. Attia, et al. 2008. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. Journal of Molecular Neuroscience 34(1): 77–87.
Chung, M.M., Y.L. Chen, D. Pei, Y.C. Cheng, B. Sun, C.J. Nicol, et al. 2015. The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent. Biochemica Biophysica Acta 1852(5): 720–731.
Jiang, T., Y. Jin-Tai, Z. Xi-Chen, W. Hu-Fu, T. Meng-Shan, L. Cao, et al. 2014. Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. British Journal of Pharmacology 171: 3146–3157.
Ullah, I., N. Ullah, M.I. Naseer, H.Y. Lee, and M.O. Kim. 2012. Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons. BMC Neuroscience 13: 11.
ACKNOWLEDGEMENTS
The authors are immensely thankful to the institutional laboratory personnel, M.G.M. Medical College, Indore, for providing technical support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
ELECTRONIC SUPPLEMENTARY MATERIAL
Below is the link to the electronic supplementary material.
ESM 1
(DOC 41 kb)
Rights and permissions
About this article
Cite this article
Rajput, M.S., Sarkar, P.D. & Nirmal, N.P. Inhibition of DPP-4 Activity and Neuronal Atrophy with Genistein Attenuates Neurological Deficits Induced by Transient Global Cerebral Ischemia and Reperfusion in Streptozotocin-Induced Diabetic Mice. Inflammation 40, 623–635 (2017). https://doi.org/10.1007/s10753-017-0509-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-017-0509-5